SynthesisProgress in cardiovascular diseases
Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.
Synthesis in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Effect of dolutegravir on 'Life's Simple 7' cardiovascular risk factors: A longitudinal analysis from Tanzania.HIV medicine · 2026Article
- Structural Cardiac Abnormalities, Ventricular Dysfunction Phenotypes, and Heart Failure Risk among Antiretroviral Therapy-treated People Living with HIV in South Africa.medRxiv : the preprint server for health sciences · 2026Article
- Association of Perinatal HIV Exposure and HIV Disease Severity With BP in Youth.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Premature "asymptomatic" peripheral artery disease and correlates among HIV-positive adults in Ghana: findings from the SCRIPT study.BMC cardiovascular disorders · 2026Article
- Characterization of Distinct Monocyte Subtypes and Immune Features Associated with HIV, Tuberculosis, and Coronary Artery Disease in a Ugandan Cohort Using Mass Cytometry.Pathogens & immunity · 2026Article
- Prevalence and Correlates of Dyslipidemia in HIV-Positive Patients at Selected Public Hospitals in Addis Ababa, Ethiopia, 2025.AIDS research and treatment · 2026Article
- A Comprehensive Review of the Manifestation of Cardiovascular Diseases in HIV Patients.Cureus · 2025Review
- Objectively Measured Physical Activity among People with and without HIV in Uganda: Associations with Cardiovascular Risk and Coronary Artery Disease.Global heart · 2025Article
- Cardioprotective effects of early versus late initiated antiretroviral treatment in adolescents with perinatal HIV-1 infection.Scientific reports · 2024Article
- Objectively measured physical activity among people with and without HIV in Uganda: associations with cardiovascular risk and coronary artery disease.medRxiv : the preprint server for health sciences · 2024Article
- Predictive model and risk analysis for coronary heart disease in people living with HIV using machine learning.BMC medical informatics and decision making · 2024Article
- Case cancellations and associated factors on the day of surgery in hospitals of Wolaita Zone, South Ethiopia.BMC surgery · 2024Article
- No Evidence for an Association of HIV and Antiviral Treatment With Changes in Framingham Cardiovascular Risk Score in the Ndlovu Cohort Study.Journal of the American Heart Association · 2024Article
- Article
- Article
- Mapping evidence on barriers to and facilitators of diagnosing noncommunicable diseases among people living with human immunodeficiency virus in low- and middle-income countries in Africa: A scoping review.SAGE open medicine · 2024Article
- Observational
- Barriers and facilitators of people living with HIV receiving optimal care for hypertension and diabetes in Tanzania: a qualitative study with healthcare professionals and people living with HIV.BMC public health · 2023Article
- Prevalence of hypertension among antiretroviral therapy naïve patients in Lagos, Nigeria.Clinical hypertension · 2023Article
- Vascular dysfunction and body mass index in African adults with HIV.BMC cardiovascular disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
As longevity has increased for people living with HIV (PLWH) in the United States and Europe, there has been a concomitant increase in the prevalence of cardiovascular disease (CVD) risk factors and morbidity in this population. Whereas the availability of HIV antiretroviral therapy has resulted in dramatic increases in life expectancy in sub-Saharan Africa (SSA), where over two thirds of PLWH reside, if and how these trends impact the epidemiology of CVD is less clear. In this review, we describe the current state of the science on how both HIV and its treatment impact CVD risk factors and outcomes among PLWH in sub-Saharan Africa, including regional factors (unique to SSA) likely to differentiate these relationships from the global North. We then outline how current regional guidelines address CVD prevention among PLWH and which clinical and structural interventions are best poised to confront the co-epidemics of HIV and CVD in the region. We conclude with a discussion of key research gaps that need to be addressed to optimally develop an actionable public health response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.